News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
866,194 Results
Type
Article (87703)
Company Profile (824)
Press Release (777654)
Multimedia
Podcasts (184)
Webinars (28)
Section
Business (233158)
Career Advice (4142)
Deals (39827)
Drug Delivery (143)
Drug Development (91337)
Employer Resources (203)
FDA (18341)
Job Trends (17414)
News (397654)
Policy (39945)
Tag
Academia (3006)
Academic (2)
Accelerated approval (24)
Adcomms (35)
Allergies (134)
Alliances (56980)
ALS (163)
Alzheimer's disease (1749)
Antibody-drug conjugate (ADC) (299)
Approvals (18424)
Artificial intelligence (569)
Autoimmune disease (125)
Automation (33)
Bankruptcy (406)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (183)
Biotechnology (487)
Bladder cancer (149)
Brain cancer (59)
Breast cancer (568)
Cancer (4527)
Cardiovascular disease (401)
Career advice (3564)
Career pathing (39)
CAR-T (278)
CDC (59)
Cell therapy (759)
Cervical cancer (36)
Clinical research (76316)
Collaboration (1553)
Company closure (5)
Compensation (1046)
Complete response letters (64)
COVID-19 (2973)
CRISPR (92)
C-suite (716)
Cystic fibrosis (145)
Data (5574)
Decentralized trials (2)
Denatured (67)
Depression (129)
Diabetes (488)
Diagnostics (7153)
Digital health (42)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (266)
Drug pricing (205)
Drug shortages (36)
Duchenne muscular dystrophy (218)
Earnings (99864)
Editorial (59)
Employer branding (25)
Employer resources (173)
Events (134348)
Executive appointments (1008)
FDA (21122)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (21)
Funding (1409)
Gene editing (199)
Generative AI (57)
Gene therapy (606)
GLP-1 (1073)
Government (5415)
Grass and pollen (8)
Guidances (379)
Healthcare (20941)
HIV (54)
Huntington's disease (44)
IgA nephropathy (79)
Immunology and inflammation (269)
Immuno-oncology (31)
Indications (70)
Infectious disease (3238)
Inflammatory bowel disease (196)
Inflation Reduction Act (16)
Influenza (110)
Intellectual property (212)
Interviews (816)
IPO (17941)
IRA (59)
Job creations (5198)
Job search strategy (2866)
Kidney cancer (17)
Labor market (88)
Layoffs (651)
Leadership (38)
Legal (10153)
Liver cancer (94)
Longevity (14)
Lung cancer (638)
Lymphoma (338)
Machine learning (37)
Management (66)
Manufacturing (719)
MASH (164)
Medical device (14957)
Medtech (14995)
Mergers & acquisitions (22854)
Metabolic disorders (1265)
Multiple sclerosis (148)
NASH (23)
Neurodegenerative disease (310)
Neuropsychiatric disorders (81)
Neuroscience (2919)
NextGen: Class of 2025 (7703)
Non-profit (5101)
Now hiring (61)
Obesity (601)
Opinion (324)
Ovarian cancer (150)
Pain (181)
Pancreatic cancer (195)
Parkinson's disease (264)
Partnered (33)
Patents (457)
Patient recruitment (380)
Peanut (58)
People (66573)
Pharmaceutical (145)
Pharmacy benefit managers (30)
Phase I (23551)
Phase II (33121)
Phase III (24962)
Pipeline (3636)
Policy (317)
Postmarket research (3554)
Preclinical (10640)
Press Release (72)
Prostate cancer (226)
Psychedelics (52)
Radiopharmaceuticals (284)
Rare diseases (773)
Real estate (7433)
Recruiting (80)
Regulatory (28450)
Reports (65)
Research institute (2713)
Resumes & cover letters (651)
Rett syndrome (22)
RNA editing (16)
RSV (81)
Schizophrenia (145)
Series A (228)
Series B (175)
Service/supplier (30)
Sickle cell disease (94)
Special edition (26)
Spinal muscular atrophy (174)
Sponsored (46)
Startups (4324)
State (2)
Stomach cancer (19)
Supply chain (106)
Tariffs (97)
The Weekly (115)
Vaccines (1093)
Venture capital (76)
Weight loss (422)
Women's health (73)
Worklife (21)
Date
Today (93)
Last 7 days (701)
Last 30 days (2779)
Last 365 days (33379)
2025 (31730)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1288)
Alabama (83)
Alaska (7)
Arizona (322)
Arkansas (14)
Asia (51249)
Australia (9008)
California (10641)
Canada (3121)
China (1020)
Colorado (449)
Connecticut (477)
Delaware (318)
Europe (117841)
Florida (1562)
Georgia (343)
Hawaii (3)
Idaho (68)
Illinois (880)
India (61)
Indiana (510)
Iowa (22)
Japan (365)
Kansas (130)
Kentucky (41)
Louisiana (28)
Maine (81)
Maryland (1388)
Massachusetts (7907)
Michigan (336)
Minnesota (616)
Mississippi (6)
Missouri (132)
Montana (34)
Nebraska (27)
Nevada (116)
New Hampshire (81)
New Jersey (2915)
New Mexico (32)
New York (2851)
North Carolina (1521)
North Dakota (10)
Northern California (4986)
Ohio (322)
Oklahoma (22)
Oregon (52)
Pennsylvania (2167)
Puerto Rico (20)
Rhode Island (47)
South America (1656)
South Carolina (60)
South Dakota (1)
Southern California (4093)
Tennessee (164)
Texas (1664)
United States (38790)
Utah (319)
Vermont (1)
Virginia (270)
Washington D.C. (85)
Washington State (897)
West Virginia (4)
Wisconsin (109)
Wyoming (2)
There are 866,194 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
December 8, 2025
·
17 min read
Press Releases
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
December 8, 2025
·
6 min read
Press Releases
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
December 8, 2025
·
1 min read
Press Releases
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
December 8, 2025
·
19 min read
Press Releases
Orna Therapeutics Presents New Data Supporting its in vivo CAR Programs for Autoimmune Diseases and Oncology at the 67th American Society of Hematology Annual Meeting
December 8, 2025
·
4 min read
Press Releases
BioInvent Presents Promising Early Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025
December 8, 2025
·
6 min read
Press Releases
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
December 8, 2025
·
5 min read
Press Releases
Secura Bio Presents Extended Follow Up Analyses from Phase 2 PRIMO Trial in Patients with Relapsed/Refractory peripheral T-cell lymphoma at the 2025 American Society of Hematology Meeting
December 8, 2025
·
8 min read
Press Releases
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
December 8, 2025
·
6 min read
Press Releases
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
December 8, 2025
·
10 min read
1 of 86,620
Next
